The TOTAM study
Recruiting
- Conditions
- Adjuvante behandeling van oestrogeenreceptor positieve (HR+) borstkanker.
- Registration Number
- NL-OMON23682
- Lead Sponsor
- Erasmus Medical Center, Rotterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Adult women (≥ 18 years of age) who are planned to start adjuvant tamoxifen therapy.
2. WHO Performance Status ≤ 1
Exclusion Criteria
1. Woman who are pregnant or breast feeding;
2. Endometrial cancer (diagnosis < 3 years ago)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To prove that TDM of tamoxifen is feasible in clinical practice.
- Secondary Outcome Measures
Name Time Method -Toxicity<br>-Dose related adverse events<br>-Compliance<br>-Cost effectiveness<br>-Incidence of tamoxifen induced non-alcoholic fatty liver disease